ArticleGenes2025
Clinical Significance of Fragile X Syndrome 2 (FXR2) in Breast Cancer.
Ohud A Alsalmi, Abrar I Aljohani, Shahad M Almutairi, Rana O Alsufyani, Abdulrahman R Alrubayee, Khalid J Alzahrani, Ghaida E Alkhammash, Hessa M Aljuaid, Hanan S Alghamdi, Fouzeyyah A Alsaeedi
Abstract read
In one paragraphArticle in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Ohud A AlsalmiDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia.
Abrar I AljohaniDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia.
Shahad M AlmutairiDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia.
Rana O AlsufyaniDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia.
Abdulrahman R AlrubayeeMedical Oncology Department, King Abdulaziz Specialist Hospital, Taif 26521, Saudi Arabia.
Khalid J AlzahraniDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia.ORCID 0000-0002-6688-0106 Ghaida E AlkhammashDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia.
Hessa M AljuaidDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia.
Hanan S AlghamdiDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia.
Fouzeyyah A AlsaeediDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia.ORCID 0000-0002-1698-6973 Funding
Taif university TU-DSPP-2025-28
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Biomarkers, TumorBreast NeoplasmsRNA-Binding ProteinsAdultAgedClinical RelevanceFemaleFragile X Messenger Ribonucleoprotein 1Gene Expression Regulation, NeoplasticHumansMiddle AgedPrognosisBiomarkers, TumorFragile X Messenger Ribonucleoprotein 1RNA-Binding Proteinsbreast cancerclinical significanceFXR2
Identifiers
PMID40149453
PMCPMC11942179
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390